PREDICTING MEASURABLE RESIDUAL DISEASE FOR ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS POSTTRANSPLANTATION

被引:0
作者
Wang, Yue-Wen [1 ,2 ]
Fu, Guo-Mei [1 ,2 ]
Xu, Lan-Ping [1 ,2 ]
Wang, Yu [1 ,2 ]
Cheng, Yi-Fei [1 ,2 ]
Zhang, Yuan-Yuan [1 ,2 ]
Zhang, Xiao-Hui [1 ,2 ]
Liu, Yan-Rong [1 ,2 ]
Liu, Kai-Yan [1 ,2 ]
Huang, Xiao-Jun [1 ,2 ]
Chang, Ying-Jun [1 ,2 ]
机构
[1] Peking Univ Peoples Hosp, Beijing, Peoples R China
[2] Peking Univ Inst Hematol, Beijing, Peoples R China
关键词
D O I
暂无
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
P516
引用
收藏
页码:498 / 498
页数:1
相关论文
共 50 条
[31]   Measurable Residual Disease Analysis by Flow Cytometry and Correlation With Molecular Measurable Residual Disease in Acute Promyelocytic Leukemia [J].
Wen, Zhihao ;
Xue, Xinran ;
Li, Shuhua ;
Liu, Yu ;
Jin, Yongmei ;
Jiang, Nenggang ;
Liao, Hongyan .
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2025, 149 (03) :262-270
[32]   Current assessment and management of measurable residual disease in patients with acute lymphoblastic leukemia in the setting of CAR-T-cell therapy [J].
Lin Minghao ;
Zhao Xiaosu ;
Chang Yingjun ;
Zhao Xiangyu .
中华医学杂志英文版, 2024, 137 (02)
[33]   Monitoring Measurable Residual/Relapsing Disease after Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Acute Lymphoblastic Leukemia [J].
Wethmar, K. ;
Matern, S. ;
Esseling, E. ;
Bruggemann, M. ;
Schliemann, C. ;
Berdel, W. E. ;
Lenz, G. ;
Stelljes, M. .
ANNALS OF HEMATOLOGY, 2019, 98 :S57-S57
[34]   Achievement of Measurable Residual Disease (MRD) Negativity Supersedes Treatment Intensity in Predicting the Outcome of Patients with Acute Myeloid Leukemia [J].
Bazinet, Alexandre ;
Kadia, Tapan M. ;
Short, Nicholas ;
Borthakur, Gautam ;
Wang, Sa A. ;
Loghavi, Sanam ;
Jorgensen, Jeffrey L. ;
Patel, Keyur P. ;
DiNardo, Courtney D. ;
Daver, Naval ;
Alvarado, Yesid ;
Haddad, Fadi ;
Pierce, Sherry A. ;
Nogueras Gonzalez, Graciela M. ;
Maiti, Abhishek ;
Andreeff, Michael ;
Jabbour, Elias ;
Konopleva, Marina ;
Huang, Xuelin ;
Kantarjian, Hagop ;
Ravandi, Farhad .
BLOOD, 2022, 140 :2267-2269
[35]   METHODS FOR THE MINIMUM RESIDUAL DISEASE MONITORING IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA [J].
Parovichnikova, E. N. ;
Mavrina, E. S. ;
Surin, V. L. ;
Savchenko, V. G. .
GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2013, 58 (03) :45-48
[36]   Updates on lymphoblastic leukemia/lymphoma classification and minimal/ measurable residual disease analysis [J].
Kovach, Alexandra E. ;
Wood, Brent L. .
SEMINARS IN DIAGNOSTIC PATHOLOGY, 2023, 40 (06) :457-471
[37]   Clinical Use of Measurable Residual Disease in Acute Myeloid Leukemia [J].
Roug, Anne Stidsholt ;
Ommen, Hans Beier .
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2019, 20 (04)
[38]   Clinical Use of Measurable Residual Disease in Acute Myeloid Leukemia [J].
Anne Stidsholt Roug ;
Hans Beier Ommen .
Current Treatment Options in Oncology, 2019, 20
[39]   Perspective on measurable residual disease testing in acute myeloid leukemia [J].
Walter, Roland B. .
LEUKEMIA, 2024, 38 (01) :10-13
[40]   Clinical Impact of Measurable Residual Disease in Acute Myeloid Leukemia [J].
Azenkot, Tali ;
Jonas, Brian A. .
CANCERS, 2022, 14 (15)